



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/35, 31/36</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/00131</b> <b>(43) International Publication Date:</b> 8 January 1998 (08.01.98)
<b>(21) International Application Number:</b> PCT/US97/10955 <b>(22) International Filing Date:</b> 24 June 1997 (24.06.97)  <b>(30) Priority Data:</b> 60/022,006                      28 June 1996 (28.06.96)                      US  <b>(71) Applicant:</b> ORTHO PHARMACEUTICAL CORPORATION [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).  <b>(72) Inventor:</b> SHANK, Richard, P.; 551 Village Circle, Blue Bell, PA 19422-1636 (US).  <b>(74) Agents:</b> CIAMPORCERO, Audley, A., Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> ANTICONVULSANT DERIVATIVES USEFUL IN TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)  <b>(57) Abstract</b>  Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ANTICONVULSANT DERIVATIVES USEFUL IN TREATING  
AMYOTROPHIC LATERAL SCLEROSIS (ALS)

BACKGROUND OF THE INVENTION

5

Compounds of Formula I:



10 are structurally novel antiepileptic compounds that are highly effective anticonvulsants in animal tests (Maryanoff, B.E, Nortey, S.O., Gardocki, J.F., Shank, R.P. and Dodgson, S.P. *J. Med. Chem.* 30, 880-887, 1987; Maryanoff, B.E., Costanzo, M.J., Shank, R.P., Schupsky, J.J., Ortegon, M.E., and Vaught J.L. *Bioorganic & Medicinal Chemistry Letters* 3, 2653-2656, 1993, McComsey, D. F. and Maryanoff, B.E., *J. Org. Chem.* 1995). These compounds are covered by US Patent No. 4,513,006. One of these compounds 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate known as topiramate has been demonstrated in clinical trials of human  
20 epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. FAUGHT, B.J. WILDER, R.E. RAMSEY, R.A. REIFE, L D. KRAMER, G.W. PLEDGER, R.M. KARIM et. al., *Epilepsia* 36 (S4) 33, 1995; S.K. SACHDEO, R.C. SACHDEO, R.A. REIFE, P. LIM and G.  
25 PLEDGER, *Epilepsia* 36 (S4) 33, 1995), and is currently marketed for the treatment of simple and complex partial seizure epilepsy with or


without secondary generalized seizures in Great Britain, Finland, the United States and Sweden and applications for regulatory approval are presently pending in numerous countries throughout the world.

5           Compounds of Formula I were initially found to possess anticonvulsant activity in the traditional maximal electroshock seizure (MES) test in mice (SHANK, R.P., GARDOCKI, J.F., VAUGHT, J.L., DAVIS, C.B., SCHUPSKY, J.J., RAFFA, R.B., DODGSON, S.J., NORTEY, S.O., and MARYANOFF, B.E., *Epilepsia* 35 450-460, 1994). Subsequent  
10       studies revealed that Compounds of Formula I were also highly effective in the MES test in rats. More recently topiramate was found to effectively block seizures in several rodent models of epilepsy (J. NAKAMURA, S. TAMURA, T. KANDA, A. ISHII, K. ISHIHARA, T. SERIKAWA, J. YAMADA, and M. SASA, *Eur. J. Pharmacol.* 254 83-89,  
15       1994), and in an animal model of kindled epilepsy (A. WAUQUIER and S. ZHOU, *Epilepsy Res.* 24, 73-77, 1996 in press).

Recent preclinical studies on topiramate have revealed previously unrecognized pharmacological properties which suggest that  
20       topiramate should be effective in treating some other neurological disorders. One of these is amyotrophic lateral sclerosis (ALS).

#### DISCLOSURE OF THE INVENTION


25           Accordingly, it has been found that compounds of the following formula I:



wherein X is O or CH<sub>2</sub>, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are as defined  
 5 hereinafter are useful in treating acute amyotrophic lateral sclerosis (ALS).

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

10 The sulfamates of the invention are of the following formula (I):




15 wherein

X is CH<sub>2</sub> or oxygen;

R<sub>1</sub> is hydrogen or alkyl; and

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently hydrogen or lower  
 20 alkoxy, when X is oxygen, R<sub>2</sub> and R<sub>3</sub> and/or R<sub>4</sub> and R<sub>5</sub> together may be a methylenedioxy group of the following formula (II):



wherein

R<sub>6</sub> and R<sub>7</sub> are the same or different and are hydrogen, lower  
 5 alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl  
 ring.


R<sub>1</sub> in particular is hydrogen or alkyl of about 1 to 4 carbons,  
 such as methyl, ethyl and iso-propyl. Alkyl throughout this  
 specification includes straight and branched chain alkyl. Alkyl  
 10 groups for R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are of about 1 to 3 carbons and  
 include methyl, ethyl, iso-propyl and n-propyl.

A particular group of compounds of formula (I) are those  
 wherein X is oxygen and both R<sub>2</sub> and R<sub>3</sub>, and R<sub>4</sub> and R<sub>5</sub> together are  
 15 methylenedioxy groups of the formula (II), wherein R<sub>6</sub> and R<sub>7</sub> are  
 both hydrogen, both alkyl, or combine to form a spiro cyclopentyl or  
 cyclohexyl ring, in particular where R<sub>6</sub> and R<sub>7</sub> are both alkyl such as  
 methyl. A second group of compounds are those wherein X is CH<sub>2</sub>  
 and R<sub>4</sub> and R<sub>5</sub> are joined to form a benzene ring. A third group of  
 20 compounds of formula (I) are those wherein both R<sub>2</sub> and R<sub>3</sub> are  
 hydrogen.

The compounds of formula (I) may be synthesized by the  
 following methods:

25

- (a) Reaction of an alcohol of the formula  $\text{RCH}_2\text{OH}$  with a chlorosulfamate of the formula  $\text{ClSO}_2\text{NH}_2$  or  $\text{ClSO}_2\text{NHR}_1$  in the presence of a base such as potassium *n*-butoxide or sodium hydride at a temperature of about  $-20^\circ$  to  $25^\circ$  C and in a solvent such as toluene, THF or dimethylformamide wherein R is a moiety of the following formula (III):



- (b) Reaction of an alcohol of the formula  $\text{RCH}_2\text{OH}$  with sulfurylchloride of the formula  $\text{SO}_2\text{Cl}_2$  in the presence of a base such as triethylamine or pyridine at a temperature of about  $-40^\circ$  to  $25^\circ$  C in a solvent such as diethyl ether or methylene chloride to produce a chlorosulfate of the formula  $\text{RCH}_2\text{OSO}_2\text{Cl}$ .

15

- The chlorosulfate of the formula  $\text{RCH}_2\text{OSO}_2\text{Cl}$  may then be reacted with an amine of the formula  $\text{R}_1\text{NH}_2$  at a temperature of about  $40^\circ$  to  $25^\circ$  C in a solvent such as methylene chloride or acetonitrile to produce a compound of formula (I). The reaction conditions for (b) are also described by T. Tsuchiya et al. in Tet. Letters, No. 36, p. 3365 to 3368 (1978).

20

- (c) Reaction of the chlorosulfate  $\text{RCH}_2\text{OSO}_2\text{Cl}$  with a metal azide such as sodium azide in a solvent such as methylene chloride or acetonitrile yields an azidosulfate of the formula  $\text{RCH}_2\text{OSO}_2\text{N}_3$  as

25

described by M. Hedayatullah in Tet. Lett. p. 2455-2458 (1975). The azidosulfate is then reduced to a compound of formula (I) wherein R<sub>1</sub> is hydrogen by catalytic hydrogenation, e.g. with a noble metal and H<sub>2</sub> or by heating with copper metal in a solvent such as

5 methanol.

The starting materials of the formula RCH<sub>2</sub>OH may be obtained commercially or as known in the art. For example, starting materials of the formula RCH<sub>2</sub>OH wherein both R<sub>2</sub> and R<sub>3</sub>, and R<sub>4</sub> and R<sub>5</sub> are

10 identical and are of the formula (II) may be obtained by the method of R. F. Brady in Carbohydrate Research, Vol. 14, p. 35 to 40 (1970) or by reaction of the trimethylsilyl enol ether of a R<sub>6</sub>COR<sub>7</sub> ketone or aldehyde with fructose at a temperature of about 25° C, in a solvent such a halocarbon, e.g. methylene chloride in the presence of a protic

15 acid such as hydrochloric acid or a Lewis Acid such as zinc chloride. The trimethylsilyl enol ether reaction is described by G. L. Larson et al in J. Org. Chem. Vol. 38, No. 22, p. 3935 (1973).

Further, carboxylic acids and aldehydes of the formulae RCOOH

20 and RCHO may be reduced to compounds of the formula RCH<sub>2</sub>OH by standard reduction techniques, e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in "Modern Synthetic

25 Reactions", 2nd Ed., pages 45 to 144 (1972).



The compounds of formula I: may also be made by the process disclosed US Patent: No.4,513,006, which is incorporated by reference herein.

5       The compounds of formula I include the various individual isomers as well as the racemates thereof, e.g., the various alpha and beta attachments, i.e., below and above the plane of the drawing, of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> on the 6-membered ring. Preferably, the oxygens of the methylenedioxy group (II) are attached on the same side of  
10   the 6-membered ring.

      The activity of the compounds of formula I in treating amyotrophic lateral sclerosis (ALS) arises from studies which indicate that topiramate exerts an antagonistic effect on the  
15   AMPA/kainate subtype of glutamate receptors (The R.W. Johnson Pharmaceutical Research Institute, Internal Research Report, Document ID Accession No. A500,960; J. W. GIBBS III, S. SOMBATI, R.J. DELORENZO, and D.A. COULTER, *Epilepsia* 37, in press, 1996), and that ALS is a chronic neurodegenerative disorder in which the  
20   regulation of glutamate is impaired (J.D. ROTHSTEIN, M. VAN KAMMEN, A.I. LEVEY, L.J. MARTIN and R.W. KUNCI, *Annals Neurology* 38, 73-84). Glutamate is utilized as the major excitatory neurotransmitter in the CNS. This function is served by a  
25   physiological process in which glutamate molecules are stored in vesicles within synaptic terminals of neurons. These molecules are released into the synaptic cleft when an action potential depolarizes the synaptic membrane, whereupon they activate specific receptors in the post-synaptic membrane of target neurons. Subsequently, the

molecules are removed from the synaptic cleft by protein "transporters" in the membrane of the synaptic terminal of the presynaptic neuron and the surrounding glial cells (astrocytes). In ALS the activity of these transport proteins appears to be

5 abnormally low, which can cause an abnormal increase in the concentration of glutamate within the synaptic cleft. This in turn can cause an excessive activation of glutamate receptors, which, if sufficient, can induce neuronal cell death (J.D. ROTHSTEIN, In: *Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis*, Edited

10 by G. Serratrice and T. Munsat, *Advances in Neurology* 68, 7-20, Lippincott-Raven Publishers, Philadelphia, 1995).

Studies have revealed that topiramate antagonizes the neuronal excitatory activity kainate, an analog of glutamate that

15 selectively activates some subtypes of glutamate receptors (J. W. GIBBS III, S. SOMBATI, R.J. DELORENZO, and D.A. COULTER, *Epilepsia* 37, in press, 1996; The R.W. Johnson Pharmaceutical Research Institute, Internal Research Reports, Document ID Accession Numbers A500,960 and 398533:1). In these studies, primary cultures enriched

20 in neurons derived from the hippocampus of fetal rats were grown in vitro for 14 to 21 days under conditions that allowed them to reach a high density and develop numerous synaptic contacts. Perforated whole-cell patch-clamp procedures were used to study electrical properties of the neuronal membranes. In this procedure electrical

25 contact between the recording electrode and the intracellular fluid is achieved by using amphotericin B to form pores in the cell membrane. This enables the cell membrane potential or current flow across the cell membrane to be recorded accurately. Kainate,

topiramate and other test compounds were microperfused onto the neurons using a multi-barrel Teflon concentration clamp pipette. Topiramate (dissolved in DMSO at 1 M, then diluted in the medium in which the neurons were incubated) was applied at concentrations of  
5 0.01, 0.1, 1, 10 or 100 and kainate was applied at concentrations 0.1 or 1 mM.

In an initial set of experiments, the antagonistic action of topiramate on kainate-evoked currents was determined as a function  
10 of the membrane potential. In experiments in which the kainate-induced membrane currents were recorded at voltage-clamped potentials ranging from -60 mV to +60 mV at 20 mV increments the magnitude of topiramate's antagonistic effect was found to decrease as the membrane was depolarized. Hence, topiramate was most  
15 effective at membrane potentials near the resting state.

The time-course of topiramate's antagonistic activity was evaluated in a second set of experiments. Kainate was pulsed into the bathing fluid for 3 sec at 1 min intervals, and once a baseline for the  
20 kainate-evoked current was established topiramate was applied constantly for a period ranging from a few min to 20 min. A partial block of the kainate-evoked current was evident within one min after topiramate was applied, but even at saturating concentrations the kainate-evoked current was reduced by only 20 to 40%. This  
25 effect was readily reversed if topiramate was withdrawn (washed out) within 5 min. However, if topiramate was applied constantly for more than 10 min, the magnitude of the antagonistic effect on the kainate-induced cell membrane currents increased markedly, and

when topiramate was withdrawn the kainate-evoked current remained depressed. Concentration-response curves were generated for both phases of topiramate's blocking effect. The EC<sub>50</sub> was approximately 1 micromolar for each phase. However, the concentration required for a maximum response was approximately 0.1 mM for the first phase (phase I block) but only approximately 0.010 mM for second (phase II block).

Because of the compelling evidence that the functional state of glutamate receptors is regulated partly by protein kinases and phosphatases (L.Y. WANG, F.A. TAVERNA, X.P. HUANG, J.F. MACDONALD, and D.R. HAMPSON, Science 259, 1173-1175, 1993), the phase II blocking effect could be explained by dephosphorylation of the kainate-activated receptors. Based on evidence that cAMP-dependent protein kinase (PKA) modulates kainate activated receptors (L.Y. WANG, F.A. TAVERNA, X.P. HUANG, J.F. MACDONALD, and D.R. HAMPSON, Science 259, 1173-1175, 1993), a set of experiments was undertaken to determine if dibutyryl cyclic AMP could restore the excitatory activity of kainate subsequent to topiramate's phase II block; i.e., cause the "irreversible" effect to be reversed. These experiments revealed that dibutyryl cyclic AMP partially or totally restored the kainate-evoked current. In another set of experiments the nonspecific phosphatase inhibitor okadaic acid was applied at 1 micromolar prior to, and during, the application of topiramate to determine if inhibiting the dephosphorylation of the kainate activated receptors would prevent the phase II blocking effect of topiramate. Okadaic acid had little effect on kainate-evoked current prior to the application of topiramate, and did not affect the

initial antagonistic effect of topiramate (phase I block); however, as expected the phase II block was prevented. These results indicate that topiramate directly or indirectly inhibits the ability of a protein kinase (PKA) to phosphorylate kainate-activatable receptors, which  
5 over time shifts the receptors into a dephosphorylated state in which they are desensitized (can not be activated).

Regardless of the mechanism by which topiramate antagonizes the action of kainate on glutamate receptors, this antagonistic effect  
10 would reduce the rate of receptor activation. In pathological situations in which there is excessive activation of glutamate receptors, as occurs in ALS, a drug-induced reduction in the activation of glutamate receptors will reduce neuronal cell death.

15 For treating amyotrophic lateral sclerosis (ALS), a compound of formula (I) may be employed at a daily dosage in the range of about 100 to 800 mg, usually two divided doses, for an average adult human. A unit dose would contain about 25 to 200 mg of the active ingredient.

20


To prepare the pharmaceutical compositions of this invention, one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a  
25 wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral

pr parations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Suppositories may be prepared, in which case cocoa butter could be used as the carrier. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent. The tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.

The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository and the like from about 50 to about 200 mg of the active ingredient.

## WHAT IS CLAIMED IS:

1. A method for treating amyotrophic lateral sclerosis (ALS)  
 5 comprising administering to a mammal afflicted with such condition  
 a therapeutically effective amount for treating such condition of a  
 compound of the formula I:




10

wherein

X is CH<sub>2</sub> or oxygen;R<sub>1</sub> is hydrogen or alkyl; and

- 15 R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently hydrogen or lower alkyl  
 and, when X is CH<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> may be alkene groups joined to form a  
 benzene ring and, when X is oxygen, R<sub>2</sub> and R<sub>3</sub> and/or R<sub>4</sub> and R<sub>5</sub>  
 together may be a methylenedioxy group of the following formula  
 (II):

20



wherein

R<sub>6</sub> and R<sub>7</sub> are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

5    2. The method of claim 1 wherein the compound of formula I is topiramate.

3. The method of claim 1, wherein the therapeutically effective amount is of from about 100 to 800 mg.

10

4. The method of claim 1, wherein the amount is of from about 25 to 200 mg.



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 97/10955

## A. CLASSIFICATION F SUBJECT MATTER

A 61 K 31/35, A 61 K 31/36

According to International Patent Classification (IPC) or to both national classification and IPC<sup>6</sup>

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4513006 A (B.E. MARYANOFF et al.) 23 April 1985 (23.04.85), abstract, claims 5-9, column 1, lines 16-33, column 3, line 15 - column 5, line 19, example 3 (cited in the application). --	1-4
A	US 4792569 A (B.E. MARYANOFF et al.) 20 December 1988 (20.12.88), abstract, claims 1,10-12, column 1, lines 20-37, column 3, line 29 - column 4, line 33. -----	1, 3, 4

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search  
10 October 1997

Date of mailing of the international search report

04.11.97

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

## ANHANG

zum internationalen Recherchen-  
bericht über die internationale  
Patentanmeldung Nr.

## ANNEX

to the International Search  
Report to the International Patent  
Application No.

## ANNEXE

au rapport de recherche inter-  
national relatif à la demande de brevet  
international n°

PCT/US 97/10955 SAE 165157

In diesem Anhang sind die Mitglieder  
der Patentfamilien der im obenge-  
nannten internationalen Recherchenbericht  
angeführten Patentdokumente angegeben.  
Diese Angaben dienen nur zur Unter-  
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family  
members relating to the patent documents  
cited in the above-mentioned inter-  
national search report. The Office is  
in no way liable for these particulars  
which are given merely for the purpose  
of information.

La présente annexe indique les  
membres de la famille de brevets  
relatifs aux documents de brevets cités  
dans le rapport de recherche inter-  
national visée ci-dessus. Les renseigne-  
ments fournis sont donnés à titre indica-  
tif et n'engagent pas la responsabilité  
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
US A 4513006	23-04-85	AT E 36149	15-08-88
		AU A1 33504784	04-04-88
		AU B2 1564842	27-08-87
		CA A1 1241951	13-09-88
		DE CO 3473143	08-09-88
		DK A0 4577784	23-09-84
		DK A 4577784	27-03-85
		DK A 1981791	09-12-91
		DK A 1982791	09-12-91
		DK A0 1981791	09-12-91
		DK A0 1982791	09-12-91
		DK B 1650003	28-09-93
		DK B 1650004	28-09-93
		DK C 1650003	08-03-94
		DK C 1650004	08-03-94
		DK A2 1388441	24-04-88
		DK A2 1388441	27-08-88
		DK A2 1388441	03-08-88
		ES A1 5336232	16-11-88
		ES A5 5336232	16-11-88
		FI A1 8600264	16-08-86
		FI A0 844376	25-09-84
		FI B 790905	31-07-89
		FI C 790905	10-11-89
		HU A2 366784	28-10-88
		HU B 194540	29-02-88
		IE B 57684	24-02-88
		JP A2 60109558	15-06-88
		JP B4 50005834	25-01-90
		JP A2 5333113	14-12-88
		KR B1 9201775	02-02-92
		NO A 843836	27-03-84
		NO B 170280	22-06-88
		NO C 170280	01-09-88
		NZ A 209494	06-02-87
		ZA A 8407550	28-05-86
		US A 4582916	15-04-86
US A 4792569	20-12-88	keine - none - rien	